Cellectar reports complete response in relapsed/refractory CNS Lymphoma patient

Cellectar Biosciences announced that a patient with primary central nervous system lymphoma enrolled in its Phase 2 CLOVER-1 Trial demonstrated a complete response according to the 2005 Response Criteria for CNS Lymphoma with total resolution of the tumor on imaging studies. Prior to study enrollment, the 61-year-old female patient was diagnosed with PCNSL, had received four lines of drug therapy including three lines of multi-drug therapy and a round of external beam radiation. She had BCL6 gene rearrangement which predicts worse outcomes and reduced survival. The patient was enrolled in the Phase 2 CLOVER-1 trial and received two cycles of iopofosine I 131 over 71 days with a total administered dose of ~100mCi. Each infusion lasted less than 30 minutes. 50 days post cycle 1 day 1 infusion, a CT scan showed a very good partial response with a 93% reduction in tumor volume. The patient was administered the second cycle of iopofosine I 131 on days 57 and 71 and demonstrated complete resolution of the tumor as determined by CT scan by day 92 from initial dosing.